FAIRFIELD, N.J., March 4 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. announced today that the Company’s Doak Dermatologics subsidiary, as the sole financial sponsor, has joined forces with The Skin Cancer Foundation, to promote the need for skin cancer screening and early treatment of skin cancer. This innovative public service campaign, The Skin Cancer Screening Tour, will begin on March 4, 2006 in San Francisco, at the 64th Annual Meeting of the American Academy of Dermatology, and will make stops at 19 cities across the United States, reaching approximately 20 million people, throughout the year. The tour is scheduled to conclude in New York City during October. A custom built vehicle, specially designed to serve as a mobile examination facility, or Mobile Diagnosis Vehicle (MDv), will be the center-piece of the campaign. The route of the Mobile Diagnosis Vehicle can be tracked at http://www.skincancerscreeningtour.com.
The MDv will be staffed by local, board-certified dermatologists in each city, ready to offer free skin cancer screenings and distribute educational materials. National and local media will be used to encourage the public to visit the MDv for screenings, or to visit local dermatologists as early as possible for a checkup. Doak plans to partner with local television and radio stations who will broadcast from the MDv site to give this public awareness program added visibility.
Bradley President and CEO, Daniel Glassman, stated, “As a provider of important topical therapies that address a variety of dermatological conditions, Doak Dermatologics has become increasingly aware of the prevalence of skin cancer. In fact, more than one million people will be diagnosed with skin cancer this year, so a minimum of an annual screening is an important part of a regular health regimen. Our goal is that the media coverage and educational materials disseminated as part of the program will encourage patients to be aware of the need to regularly visit their dermatologist.”
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands; and A. Aarons, which will market authorized generic versions of Doak and Kenwood therapies.
Important announcement:
Doak Dermatologics continues its dedicated support of the American Academy of Dermatology that dates to the organization’s inception. Doak will be an Emerald sponsor of the 64th Annual Meeting of the AAD, to be held in San Francisco, CA, March 3-7, 2006.
Daniel Glassman will present at the Raymond James & Associates 27th Annual Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando, FL, March 7, 2006.
MediGene AG POLYPHENON(R) E Ointment agreement to be presented at an Investor Conference, in Frankfurt, Germany. March 22, 2006.
Daniel Glassman will present at the CIBC World Markets Annual Specialty Pharmaceutical & Biotechnology Conference, to be held at the Millennium Broadway Hotel in New York City, April 4-5, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16-18th, 2006.
Daniel Glassman will present a case study on Optimizing Lifecycle Management for a Product with Limited Patent Protection at the MedAd News’ Specialty Pharmaceuticals Summit, June 6-8, 2006 at 8:45 AM at the Park Hyatt, Philadelphia, PA.
Bradley Pharmaceuticals, Inc.
CONTACT: Investor, Anthony Griffo of Bradley Pharmaceuticals, Inc.,+1-973-882-1505, ext. 313
